Integration of Oncogenes Via Sleeping Beauty As a Mouse Model of HPV16 Oral Tumors and Immunologic Control
Overview
Oncology
Authors
Affiliations
Human papillomavirus type 16 (HPV16) is the etiologic factor for cervical cancer and a subset of oropharyngeal cancers. Although several prophylactic HPV vaccines are available, no effective therapeutic strategies to control active HPV diseases exist. Tumor implantation models are traditionally used to study HPV-associated buccal tumors. However, they fail to address precancerous phases of disease progression and display tumor microenvironments distinct from those observed in patients. Previously, K14-E6/E7 transgenic mouse models have been used to generate spontaneous tumors. However, the rate of tumor formation is inconsistent, and the host often develops immune tolerance to the viral oncoproteins. We developed a preclinical, spontaneous, HPV16 buccal tumor model using submucosal injection of oncogenic plasmids expressing HPV16-E6/E7, NRas , luciferase, and sleeping beauty (SB) transposase, followed by electroporation in the buccal mucosa. We evaluated responses to immunization with a pNGVL4a-CRT/E7(detox) therapeutic HPV DNA vaccine and tumor cell migration to distant locations. Mice transfected with plasmids encoding HPV16-E6/E7, NRas , luciferase, and SB transposase developed tumors within 3 weeks. We also found transient anti-CD3 administration is required to generate tumors in immunocompetent mice. Bioluminescence signals from luciferase correlated strongly with tumor growth, and tumors expressed HPV16-associated markers. We showed that pNGVL4a-CRT/E7(detox) administration resulted in antitumor immunity in tumor-bearing mice. Lastly, we demonstrated that the generated tumor could migrate to tumor-draining lymph nodes. Our model provides an efficient method to induce spontaneous HPV tumor formation, which can be used to identify effective therapeutic interventions, analyze tumor migration, and conduct tumor biology research. .
Anchoori R, Tseng S, Tsai H, Palande V, Rudek M, Roden R PLoS One. 2024; 19(7):e0305710.
PMID: 38990850 PMC: 11239005. DOI: 10.1371/journal.pone.0305710.
Lim L, Hu M, Fan D, Tu H, Tsai Y, Cheng M Vaccines (Basel). 2024; 12(4).
PMID: 38675812 PMC: 11053987. DOI: 10.3390/vaccines12040430.
Genetically engineered mouse models of head and neck cancers.
Tasoulas J, Srivastava S, Xu X, Tarasova V, Maniakas A, Karreth F Oncogene. 2023; 42(35):2593-2609.
PMID: 37474617 PMC: 10457205. DOI: 10.1038/s41388-023-02783-7.
Development and anticancer properties of Up284, a spirocyclic candidate ADRM1/RPN13 inhibitor.
Anchoori R, Anchoori V, Lam B, Tseng S, Das S, Velasquez F PLoS One. 2023; 18(6):e0285221.
PMID: 37315065 PMC: 10266688. DOI: 10.1371/journal.pone.0285221.
Preclinical models in head and neck squamous cell carcinoma.
Chaves P, Garrido M, Oliver J, Perez-Ruiz E, Barragan I, Rueda-Dominguez A Br J Cancer. 2023; 128(10):1819-1827.
PMID: 36765175 PMC: 10147614. DOI: 10.1038/s41416-023-02186-1.